Antibody-dependent cell-mediated cytotoxicity (ADCC) in familial myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

References

• Jason LA, Johnson M. Solving the ME/CFS criteria and name conundrum: the aftermath of IOM. fatigue: Biomedicine. Health & Behavior. 2020;8:97–107.
   Google Scholar
• Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington (DC): National Academies Press; 2015.
   Google Scholar
• Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. 1994;121(12):953–959.
   PubMed Web of Science ®Google Scholar
• Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. Br Med J. 2006;333(7568):575.
   PubMedGoogle Scholar
• Komaroff AL. Advances in understanding the pathophysiology of chronic fatigue syndrome. Jama. 2019. Jul 5. doi: https://doi.org/10.1001/jama.2019.8312. Online ahead of print.
   Google Scholar
• Friedberg F. Legitimizing myalgic encephalomyelitis/chronic fatigue syndrome: indications of change over a decade. fatigue: biomedicine. Health & Behavior. 2019;8:24–31.
   Google Scholar
• Reynolds KJ, Vernon SD, Bouchery E, et al. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc. 2004;2(1):4.
   PubMedGoogle Scholar
• Shimosako N, Kerr JR. Use of single-nucleotide polymorphisms (SNPs) to distinguish gene expression subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Clin Pathol. 2014;67(12):1078–1083.
   PubMed Web of Science ®Google Scholar
• Janal MN, Ciccone DS, Natelson BH. Sub-typing CFS patients on the basis of ‘minor’ symptoms. Biol Psychol. 2006;73(2):124–131.
   PubMed Web of Science ®Google Scholar
• Nagy-Szakal D, Barupal DK, Lee B, et al. Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics. Sci Rep. 2018;8(1):10056.
   PubMedGoogle Scholar
• Levine PH, Whiteside TL, Friberg D, et al. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998;88(1):96–104.
   PubMedGoogle Scholar
• Walsh CM, Zainal NZ, Middleton SJ, et al. A family history study of chronic fatigue syndrome. Psychiatr Genet. 2001;11(3):123–128.
   PubMed Web of Science ®Google Scholar
• Eaton-Fitch N, du Preez S, Cabanas H, et al. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8(1):279.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–3725.
   PubMed Web of Science ®Google Scholar
• Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100(5):1059–1070.
   PubMed Web of Science ®Google Scholar
• Daugherty SA, Henry BE, Peterson DL, et al. Chronic fatigue syndrome in northern Nevada. Rev Infect Dis. 1991;13(Suppl 1):S39–S44.
   PubMedGoogle Scholar
• Loebel M, Strohschein K, Giannini C, et al. Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome. PLoS ONE. 2014;9(1):e85387.
   PubMed Web of Science ®Google Scholar
• Beqaj SH, Lerner AM, Fitzgerald JT. Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. J Clin Pathol. 2008;61(5):623–626.
   PubMed Web of Science ®Google Scholar
• Shapiro JS. Does varicella-zoster virus infection of the peripheral ganglia cause chronic fatigue syndrome? Med Hypotheses. 2009;73(5):728–734.
   PubMed Web of Science ®Google Scholar
• Komaroff AL. Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol. 2006;37(Suppl 1):S39–S46.
   PubMedGoogle Scholar
• Chapenko S, Krumina A, Logina I, et al. Association of active human herpesvirus-6, -7 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv Virol. 2012;2012:205085.
   PubMedGoogle Scholar
• Kerr JR, Tyrrell DA. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr Pain Headache Rep. 2003;7(5):333–341.
   PubMedGoogle Scholar
• Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A. 2017;114(34):E7150–E71e8.
   PubMed Web of Science ®Google Scholar
• Soto NE, Straus SE. Chronic fatigue syndrome and Herpesviruses: the Fading evidence. Herpes. 2000;7(2):46–50.
   PubMedGoogle Scholar
• Sung AP, Tang JJ, Guglielmo MJ, et al. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. J Immunol Methods. 2018;452:63–72.
   PubMed Web of Science ®Google Scholar
• Strauss-Albee DM, Fukuyama J, Liang EC, et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med. 2015;7(297):297ra115. doi: https://doi.org/10.1126/scitranslmed.aac5722.
   Google Scholar
• Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item health Survey 1.0. Health Econ. 1993;2(3):217–227.
   PubMedGoogle Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18(5):728–733.
   PubMed Web of Science ®Google Scholar
• Mata MM, Mahmood F, Sowell RT, et al. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays. J Immunol Methods. 2014;406:1–9.
   PubMed Web of Science ®Google Scholar
• Langenskiold C, Mellgren K, Abrahamsson J, et al. Determination of blood cell subtype concentrations from frozen whole blood samples using TruCount beads. Cytometry B Clin Cytom. 2016;94(4):660-666.
   PubMed Web of Science ®Google Scholar
• Milush JM, Lopez-Verges S, York VA, et al. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology. 2013;10(158). doi: https://doi.org/10.1186/1742-4690-10-158.
   Google Scholar
• Hudig D, Hunter KW, Diamond WJ, et al. Properties of human blood monocytes. I. CD91 expression and log orthogonal light scatter provide a robust method to identify monocytes that is more accurate than CD14 expression. Cytometry B Clin Cytom. 2014;86(2):111–120.
   PubMed Web of Science ®Google Scholar
• Chung S, Lin YL, Reed C, et al. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. J Immunol Methods. 2014;407:63–75.
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–4402.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Bruggemann M, et al. Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism. J Immunol Methods. 2005;306(1-2):128–136.
   PubMed Web of Science ®Google Scholar
• Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–577.
   PubMed Web of Science ®Google Scholar
• Moller MJ, Kammerer R, von Kleist S. A distinct distribution of natural killer cell subgroups in human tissues and blood. Int J Cancer. 1998;78(5):533–538.
   PubMed Web of Science ®Google Scholar
• McLellan T, Jorde LB, Skolnick MH. Genetic distances between the Utah Mormons and related populations. Am J Hum Genet. 1984;36(4):836–857.
   PubMed Web of Science ®Google Scholar
• Tsang A-S MW, Nagelkerke SQ, Bultink IE, et al. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford). 2016;55(5):939–948.
   PubMed Web of Science ®Google Scholar
• Romain G, Senyukov V, Rey-Villamizar N, et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood. 2014;124(22):3241–3249.
   PubMed Web of Science ®Google Scholar
• See DM, Broumand N, Sahl L, et al. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology. 1997;35(3):229–235.
   PubMed Web of Science ®Google Scholar
• Theorell J, Bileviciute-Ljungar I, Tesi B, et al. Unperturbed cytotoxic lymphocyte phenotype and function in myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. 2017;8(723). doi: https://doi.org/10.3389/fimmu.2017.00723. eCollection 2017.
   Google Scholar
• van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91(1):79–118.
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1):S88–S95.
   PubMed Web of Science ®Google Scholar